| Literature DB >> 33575418 |
Krista R Wigginton1, Peter J Arts1, Herek L Clack1, William J Fitzsimmons2, Mirko Gamba3, Katherine R Harrison1, William LeBar4, Adam S Lauring2, Lucinda Li1, William W Roberts5,6, Nicole C Rockey1, Jania Torreblanca4, Carol Young4, Loïc G Anderegg7,8, Amy M Cohn9, John M Doyle7,8, Cole M Meisenhelder7, Lutgarde Raskin1, Nancy G Love1, Keith S Kaye2.
Abstract
BACKGROUND: Due to unprecedented shortages in N95 filtering facepiece respirators, healthcare systems have explored N95 reprocessing. No single, full-scale reprocessing publication has reported an evaluation including multiple viruses, bacteria, and fungi along with respirator filtration and fit.Entities:
Keywords: N95; decontamination; inactivation; reprocessing; virus
Year: 2020 PMID: 33575418 PMCID: PMC7863868 DOI: 10.1093/ofid/ofaa610
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Filtration Performance and Fit Test Results for 3M 1860 FFRs After Treatment for Decontamination
| Decontamination Treatment | Minimum Filtration Efficiencya,b (No. of Treatment Cyclesc) | Fit Test Outcome No. Passed/No. Tested After (No. Cycles) |
|---|---|---|
| Low RH heat | >95% (10) | NT |
| Moderate RH heat | >98% (10) | 3/3 (5) |
| Bioquell HPV | >99% (5) | 5/5 (5) |
| HPGP | >74% (5)d | NT |
| EtO | >99% (1) | NT |
Abbreviations: EtO, ethylene oxide; FFR, filtering facepiece respirators; HPGP, hydrogen peroxide gas plasma; HPV, hydrogen peroxide vapor; NT, not tested; RH, relative humidity.
aAccording to National Institute for Occupational Safety and Health guidelines, an N95 respirator is acceptable if filtration efficiency is larger than 95%.
bIn all cases, pressure differential across FFR was maintained at 17.0 ± 0.5 mm H2O.
cSingle-cycle duration values, by treatment method using the method designated under Materials and Methods.
dMinimum filtration efficiency was <95% after 3 treatments.
Figure 1.Virus inactivation on N95 respirators with pulsed xenon ultraviolet (UV) treatment. Studies A and B conducted on 2 different days. Arrows identify samples that exceeded assay detection limits after treatment. Asterisk indicates negligible inactivation. Replicates (n = 2) for each treatment condition are shown. Viruses were deposited on the coupons in either phosphate-buffered saline (PBS) or influenza A virus (IAV) media (Supplement Table S4 and Supplement Table S5). MHV, murine hepatitis virus.
Inactivation Data for Bacterial and Fungus Indicators
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatmenta | Measured LRV | CFUs on Coupons | Measured LRV | CFUs on Coupons | Measured LRV | CFUs on Coupons | Tablete | Measured LRV | CFUs on Coupons |
| HPV Condition 1d | 1.0 | 3.3 × 103/3.2 × 104 | >3.8 | <1.3 × 102f/>8.0 × 105 | >1.4 | <1.3 × 102f/3.3 × 103 | Negative | >1.2 | <1.3 × 102f/3.3 × 103 |
| HPV Condition 2d | >2.3 | 3.6 × 103/>8.0 × 105 | >3.8 | <1.3 × 102f/>8.0 × 105 | >3.0 | <1.3 × 102f/1.4 × 105 | Negative | >3.8 | 6.7 × 101/>8.0 × 105 |
| HPV Condition 2d | >1.6 | 1.8 × 104/>8.0 × 105 | NT | 2.8 | 6.7 × 101/4.0 × 104 | Negative | NT | ||
| UV-PX, round 1 | >0.3 | 1.4 × 106/>2.4 × 106 | >1.0 | <1.7 × 102f/1.3 × 103 | 0 | 1.4 × 105/1.4 × 105 | Positive | NT | |
| UV-PX, round 2 | 0.5 | 4.2 × 105/1.3 × 106 | 0.85 | 4.0 × 102/2.8 × 103 | 0.33 | 1.0 × 104/2.1 × 104 | NT | 2.3 | 2.8 × 103/5.6 × 105 |
| Moderate RH heat, round 1 | >2.4 | 8.8 × 103/>2.4 × 106 | >1.0 | <1.7 × 102f/1.3 × 103 | 0.10 | 1.1 × 105/1.4 × 105 | Positive | NT | |
| Moderate RH heat, round 2 | >3.2 | <8.0 × 102f/1.3 × 106 | >0.5 | <8.0 × 102f/2.8 × 103 | 0.60 | 5.6 × 103/2.1 × 104 | NT | >2.8 | <8.0 × 102/5.6 × 105 |
| UV-PX + moderate RH heat, round 1 | >2.7 | 4.3 × 103/>2.4 × 106 | >1.0 | <1.7 × 102f/1.3 × 103 | 0.17 | 9.2 × 104/1.4 × 105 | Positive | NT | |
| UV-PX + moderate RH heat, round 2 | >3.2 | <8.0 × 102f/1.3 × 106 | >0.5 | <8.0 × 102f/2.8 × 103 | 1.4 | 1.6 × 103/2.1 × 104 | NT | >2.8 | <8.0 × 102/5.6 × 105 |
Abbreviations: CFUs, colony-forming units; HPV, hydrogen peroxide vapor; LRV, log reduction value; NT, not tested; RH, relative humidity; UV-PX, pulsed xenon UV-C.
aTreatments include condition 1 (short run) and condition 2 (long run that simulates the Battelle protocol); UV-PX treatment condition is the same for all rounds at fluence rate = 24 mJ/cm2; low RH heat is in hospital instrument washer dry cycle; moderate RH heat round 1 is with sealed containers in the hospital instrument washer with drying cycle; moderate RH heat round 2 is with the hospital humidity controlled oven.
bLRV = (−1) × log10(CFU remaining after treatment/CFU applied).
cThe average viable, extractable CFU remaining after treatment/viable, extractable CFU per untreated control, for coupons.
dColonies were applied on the backside of respirators because of difficulty in applying to hydrophobic front side; consequently, recoveries were higher for E coli.
eResults shown are for treated Geobacillus tablets. Untreated controls are not shown but were always positive.
f No colonies detected so <1 colony assumed for calculations.
Figure 2.Virus removal with moderate relative humidity (RH) heat. Virus removal with moderate RH heat using (A) Ziploc container with ~70% RH and 80°C and (B) an industrial-scale temperature and humidity-controlled oven with ~50% RH and 82°C. Replicates (n = 2) for each treatment condition are shown. Arrows identify samples that exceeded assay detection limits after treatment. Viruses were deposited on the coupons in either phosphate-buffered saline (PBS) or influenza A virus (IAV) media (Supplement Table S4 and Supplement Table S5). MHV, murine hepatitis virus.
Figure 3.Virus removal with Bioquell hydrogen peroxide vapor (HPV) system. Virus removal with Bioquell hydrogen peroxide vapor (HPV) system with either (A) Condition 1 or (B) Condition 2. Replicates of treated coupons (n = 2) are shown. Arrows illustrate samples that exceeded assay detection limits after treatment. Viruses were deposited on the coupons in either phosphate-buffered saline (PBS) or influenza A virus (IAV) media (Supplement Table S4 and Supplement Table S5). MHV, murine hepatitis virus.
A Comparison of Different Treatment Options Relative to Practical Considerations
| Microbiologic Activity | Practical and Operational Considerations for Treatmenta | ||||
|---|---|---|---|---|---|
| Treatment Modality | Viruses | Bacteria | Time Needed/Cycle | Space Needed | Maintenance Costsb |
| UV-PX | + | + | <1 hour | Moderate | $ |
| Moist heat | ++++ | +++ c | <1 hour | Least | $ |
| HPV | +++ | +++ d | ~8 hours | Most | $$$ |
Abbreviations: HPV, hydrogen peroxide vapor; UV-PX, pulsed xenon UV-C.
aEstimates based on the filtering facepiece respirator (FFR) capacity per treatment cycle: hydrogen peroxide vapor (HPV) – 800 (~ 100/hour); moist heat – 75 (~ 75/hour); pulsed xenon UV-C (UV-PX) – 200 (~ 200/hour).
bCost does not including initial purchase.
cMinimal activity against spore-forming bacteria (via Geobacillus experiments).
dDid not completely eradicate Staphylococcus aureus.